6533b7cffe1ef96bd12584d4

RESEARCH PRODUCT

Strategies in Glioma-Surgery

Sven R. KantelhardtAlf Giese

subject

Oncologymedicine.medical_specialtybusiness.industryAnaplastic oligodendrogliomaGlioma surgeryNewly diagnosedDiseasemedicine.diseaseWell differentiatednervous system diseasesInternal medicineGliomaEpidemiologymedicinebusinessneoplasmsAnaplastic astrocytoma

description

1.1 Epidemiology and classification of gliomas Malignant glioma is one of the most feared diseases in the industrialized nations. About 77% of all malignant tumors within the central nervous system are gliomas. There are about 18.000 newly diagnosed cases annually within the USA (9/100.000 inhabitants per year) and the disease causes about 13.000 deaths each year. Statistically this is a higher loss of life-time than all other tumor-entities together (Schwartzbaum et al., 2006). About 45-50% of these gliomas are histologically classified as gliobalstoma multiforme (GBM) the most aggressive type of glioma which is classified as WHO grade IV (following the classification of Kleihues et al., 2000). 20-30% are so called anaplastic astrocytoma and the rarer anaplastic oligodendroglioma (WHO grade III), while about 16-8% are classified as low-grade gliomas (WHO grade I and II). Generally they show a less aggressive behaviour and a comparatively well differentiated appearance.

yearjournalcountryeditionlanguage
2011-09-22
http://www.intechopen.com/articles/show/title/strategies-in-glioma-surgery